Is Assembly Biosciences, Inc. (NASDAQ:ASMB) a buy in 2026?
Yes, on balance. The Compass leans toward accumulating Assembly Biosciences, Inc. at current levels.
A Gilead-backed antiviral platform trading like a single-shot biotech, with four Phase 1 readouts converging into an under-owned herpes and HDV story.
Where ASMB is headed
Assembly Biosciences in mid-2027 looks nothing like the $700M shell most generalists still remember from the failed HBV core inhibitor days. By then, ABI-5366 and ABI-1179 should have delivered full Phase 2 data in recurrent genital herpes, a market Gilead pegs at ~$3B annually and one that has seen zero meaningful innovation since valacyclovir went generic in 2009. If either helicase-primase inhibitor shows what the Phase 1a viral shedding data hinted at, monthly or quarterly dosing that suppresses reactivation, this becomes the first genuine therapeutic advance in genital herpes in a generation. Gilead has an option to co-develop through the 2023 collaboration, and their $84.75M upfront plus $75M equity investment at a premium tells you they intend to exercise it.
Read the full Compass Direction on ASMB
The complete destination call, the overlooked angle, milestones, and bull, base, and bear price scenarios (around $34.38).
See the full ASMB analysisGet calls like this, free
Join the Alexandria e-letter for forward-looking verdicts, earnings intelligence, and the contrarian reads the crowd misses. Twice a week, no noise.
Free forever. Unsubscribe anytime. We never share your email.
Frequently asked questions
Is Assembly Biosciences, Inc. (NASDAQ:ASMB) a buy in 2026?
Yes, on balance. The Compass leans toward accumulating Assembly Biosciences, Inc. at current levels. A Gilead-backed antiviral platform trading like a single-shot biotech, with four Phase 1 readouts converging into an under-owned herpes and HDV story.
What is ASMB's Compass Score?
Assembly Biosciences, Inc. scores 77/100 on Alexandria's Compass, placing it in the "Favorable" tier. Scores blend eight factors and update weekly.
What is the price target for ASMB?
Alexandria's full Compass Direction includes bull, base, and bear price scenarios with the valuation math behind each. Read the full breakdown on the ASMB page.
Compass verdicts are AI-generated, forward-looking editorial research from publicly available data, not investment advice or a recommendation regarding any security. Scores and verdicts update as the data changes.